Erdafitinib Tackles an Unmet Need in Urothelial Carcinoma

As the first targeted therapy in bladder cancer, erdafitinib (Balversa) expands the limited treatment options for the subset of patients with urothelial carcinoma who harbor FGFR3 or FGFR2 genetic alterations. In results from a phase II clinical trial (NCT02365597), erdafitinib demonstrated a robust response rate and was tolerable in a population with a typically poor prognosis, said Arlene O. Siefker-Radtke, MD.
... to read the full story